

Inova Pulmonary Hypertension Program PH-Related Publications

2016

- Shin S, **King CS**, Puri N, **Shlobin OA**, **Brown AW**, **Ahmad S**, **Weir N**, **Nathan SD**. Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. *Eur Respir J* 2016; 47:1445–1451.
- Mazimba S, Mejia-Lopez E, Black G, **Kennedy JLW**, Bergin J, Tallaj JA, Abuannadi M, Mihalek AD, Bilchick KC. Diastolic pulmonary gradient predicts outcomes in group 1 pulmonary hypertension (analysis of the NIH primary pulmonary hypertension registry). *Respiratory Medicine*, 2016; 119: 81-86, PMID 27692153.
- Mazimba S, **Kennedy JLW**, Zhuo D, Abuannadi M, Bergin J, Tallaj K, Bilchick KC. Decreased pulmonary artery proportional pulse pressure after pulmonary artery catheterization optimization for advanced heart failure is associated with adverse clinical outcomes. *Journal of Cardiac Failure*, 2016; 22(12): 954-61, PMID 27095529.
- **Shlobin OA**, **Nathan SD**. Rare ILD and PH. For *Pulmonary Hypertension and Interstitial lung disease 2016*. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan.
- **King CS**, **Nathan SD**. Treatment of Pulmonary Hypertension in Interstitial Lung Disease. For *Pulmonary Hypertension and Interstitial lung disease 2016*. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan.
- Shah R, Patel DB, Mankad AK, Rennyson SL, **Tang DG**, Quader MA, Smallfield MS, Kasirajan V, Shah KB. Pulmonary Hypertension after Heart Transplantation in Patients Bridged with the Total Artificial Heart. *ASAIO J* 2016; 62(1):69-73. doi: 10.1097/MAT.000000000000298.
- Fischer A, Gillies H, Blair C, Tislow JD, **Nathan SD**. Ambrisentan Response in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension- Subgroup Analysis of the ARIES-E Clinical Trial. *Respiratory Medicine* 2016; 117:254-263.

2017

- Jose A, **King C**, **Shlobin OA**, **Kiernan J**, **Cossa N**, **Nathan SD**. Ventricular diastolic pressure ratio as a marker of treatment response in pulmonary hypertension. *Chest* 2017; 152(5):980-989.
- Mwansa H, Bilchick KC, Parker AM, Harding WC, Ruth B, **Kennedy JLW**, Mysore M, Kwon Y, Mihalek AD, Mazimba S. Decreased pulmonary artery proportional pulse pressure is associated with increased mortality in group 1 pulmonary hypertension. *Clinical Cardiology*, 2017; 40(11): 988-992, PMID 28692753.
- Mazimba S, Holland E, Nagarajan V, **Kennedy JLW**, Bilchick K. Obesity paradox in group 1 pulmonary hypertension: analysis of the NIH pulmonary hypertension registry. *International Journal of Obesity*, 2017; 41(8): 1164-1168, PMID 28209971.
- **Shlobin OA**, Baughman R. Sarcoidosis associated pulmonary hypertension. *Seminars in Respiratory Critical Care Medicine* 2017; 38:450-462.
- **Shlobin OA**, **Brown AW**, **Nathan SD**. Pulmonary hypertension in diffuse parenchymal lung diseases. *Chest* 2017 Jan; 151(1):204-214.

2018

- Mysore MM, Bilchick KC, Ababio P, Ruth BK, Harding WC, Breathett K, Chadwell K, Patterson B, Mwansa H, Jeukeng CM, Kwon Y, **Kennedy JLW**, Mihalek AD, Mazimba S. Right atrial to left atrial volume index ratio is associated with increased mortality in patients with pulmonary hypertension. *Echocardiography* 2018; 35(11): 1729-1735, PMID 30315607.
- Smith LA and **Kennedy JLW**. Pulmonary Hypertension and Related Disorders. 2018; in M. Ragosta (ed.) *Textbook of Clinical Hemodynamics*, 2nd edition. Philadelphia, Elsevier.
- Behr J, **Nathan SD**, Harari S, Wyuts W, Kirchgassler K, Bengus M, Gilberg F, Wells A. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and pulmonary hypertension: A Phase IIb randomised double-blind placebo-controlled study. *Respir Med* 2018 May; 138:13-20. doi: 10.1016/j.rmed.2018.03.019.

- **King CS, Brown AW, Shlobin O**, Weir N, Libre M, Franco-Palacios D, Ahmad S, **Nathan SD**. Incidence and Impact of WHO Group 3 Pulmonary Hypertension in Idiopathic Nonspecific Interstitial Pneumonia. *Eur Respir J* 2018; 52: 1800545. doi: 10.1183/13993003.00545-2018
- Baughman RP, **Shlobin OA**, Alhamad EH, Cal GJ, Porquero EC, Birring S, Lower EE, Engel PJ, Nathan SD. Clinical features of sarcoidosis associated pulmonary hypertension: results of a multi-national registry. *Respir Med* 2018; 139:72-78. doi: 10.1016/j.rmed.2018.04.015.
- Anderson M, Morris DL, **Tang D**, Batsides G, Kirtane A, Hanson I, Meraj P, Kapur NK, O'Neill W. Outcomes of patients with right ventricular failure requiring short-term hemodynamic support with the Impella RP device. *J Heart Lung Transplant* 2018 Dec; 37(12):1448-1458. doi: 10.1016/j.healun.2018.08.001.
- Arun J, **King CS, Shlobin OA, Brown AW**, Wang C, **Nathan SD**. Pulmonary Hemodynamic Responses Predict Outcomes in Patients with Fibrotic Lung Disease Undergoing Exercise Right Heart Catheterization Testing. *Eur Respir J* 2018; 52:1801015.
- Jose A, Franco-Palacios D, **King CS**, Gomberg-Maitland M. A 70 year old woman presenting with diarrhea and in-hospital cardiac arrest. *Chest* 2018; 153(1):e5-e8.
- Elinoff JM, Agarwal R, Barnett C, Benza RL, Cuttica MJ, Gharib AH, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig E, **Shlobin OA**, Steen VD, Zamanian RT, and Solomon MA. Challenges in pulmonary hypertension: icebergs in the water: A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association symposium report. *AJRCCM* 2018; 198(2):166-174.
- Rhodes C et al. (**Nathan SD** among 118 co-authors). Genetic determinants of risk and survival in pulmonary arterial hypertension. *Lancet Res Med* 2019; 7:227-238.

2019

- **Nathan SD**, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W. Pulmonary Hypertension in Chronic Lung Disease and Hypoxia. *ERJ* 2019; 53(1):1801914.
- Aras MA, **Pspotka MA**, De Marco T. Pulmonary Hypertension Due to Left Heart Disease: an Update. *Curr Cardiol Rep* 2019 May 27; 21(7):62. doi: 10.1007/s11886-019-1149-1. PMID: 31134443.
- Ruth BK, Bilchick KC, Mysore MM, Mwansa H, Harding WC, Kwon Y, **Kennedy JLW**, Mazurek JA, Mihalek AD, Smith LA, Mejia-Lopez E, Parker AM, Welch TS, Mazimba S. Increased pulmonary-systemic pulse pressure ratio is associated with increased mortality in group 1 pulmonary hypertension. *Heart, Lung, and Circulation* 2019; 28(7): 1059-1066, PMID 30006114. Mazimba S, Welch TS, Mwansa H, Breathett KK, **Kennedy JLW**, Mihalek AD, Harding WC, Mysore MM, Zhuo DX, Bilchick KC. Hemodynamically derived pulmonary artery pulsatility index predicts mortality in pulmonary arterial hypertension. *Heart, Lung, and Circulation* 2019; 28(5): 752-760, PMID 29748060.
- Aras MA, **Pspotka MA**, De Marco T. Pulmonary Hypertension Due to Left Heart Disease: an Update. *Curr Cardiol Rep* 2020; 21:62.
- Schubert SA, Mehaffey JH, Booth A, Yarboro LT, Kern JA, **Kennedy JLW**, Ailawadi G, Mazimba S. Pulmonary-systemic pressure ratio correlates with morbidity in cardiac valve surgery. *Journal of Cardiothoracic and Vascular Anesthesia* 2019; 33(3): 677-682, PMID 30243869.
- Mabe D, **Shlobin O**, Bogar L, **Nathan S, Brown A, Ahmad K, Aryal S**, Murphy C, **King C**. Extracorporeal Membrane Oxygenation as a Bridge to Initial Medical Therapy in a Patient With Decompensated Pulmonary Arterial Hypertension Presenting With Biventricular Failure. *Journal of Medical Cases, North America*, 2019 (10).
- Woolstenhulme JG, Guccione AA, Herrick JE, Collins JP, **Nathan SD**, Chan LE, Keyser RE. Left Ventricular Function Before and After Aerobic Exercise Training in Women Who Have Pulmonary Arterial Hypertension. *Journal of Cardiopulmonary Rehabilitation and Prevention* 2019, 39(2):118-126.
- Mazimba S, Welch TS, Mwansa H, Breathett KK, **Kennedy JLW**, Mihalek AD, Harding WC, Mysore MM, Zhuo DX, Bilchick KC. Hemodynamically derived pulmonary artery pulsatility index predicts mortality in pulmonary arterial hypertension. *Heart, Lung, and Circulation*, 2019; 28(5): 752-760, PMID 29748060.

- **Nathan SD**, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez F, Corte T, Keogh A, Leuchte H, Mogulkoc N, Ulrich S, Wuyts W, Shah S, Yao M, Boateng F, Wells A. Riociguat for Idiopathic Interstitial Pneumonia-Associated Pulmonary Hypertension: The Randomized RISE-IIP Study. *Lancet Res Med* 2019; 7:780-790.
- Sonti R, Gersten RA, Barnett SD, Brown AW, **Nathan SD**. Multimodal Noninvasive Prediction of Pulmonary Hypertension in IPF. *Clin Respir J*. 2019; 13(9):567-573. doi: 10.1111/crj.13059.

2020

- Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Grinnan D, Klinger JR, Bolivar L, **Shlobin OA**, Frantz RP, Sager JS, Mathai SC, Kawut S, Leary P, Gray MP, Popat RA, Zamanian RT. EmPHasis-10 as a Measure of Health-Related Quality of Life in Pulmonary Arterial Hypertension: data from PHAR. *Eur Respir J* 2020 Nov 26. [Epub ahead of print] PubMed PMID: 33243844
- Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, Maloney J, De Marco T, Ivy D, Thenappan T, Sager JS, Ryan JJ, Mazimba S, Hirsch R, Chakinala M, **Shlobin O**, Lammi M, Zwicke D, Robinson J, Benza RL, Klinger J, Grinnan D, Mathai S, Badesch D. Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. *Pulm Circ* 2020 Oct-Dec;10(4):2045894020964342. PubMed PMID: 33240488
- Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, Klinger J, Lammi M, Mazimba S, Sager J, **Shlobin O**, Simon M, Thenappan T, Grinnan D, Ventetuolo C, Al-Naamani N. Prediction of Health-Related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR). *Am J Respir Crit Care Med* 2020 Nov 19. [Epub ahead of print] PubMed PMID: 33211974
- Min J, Feng R, Badesch D, Berman-Rosenzweig E, Burger C, Chakinala M, De Marco T, Feldman J, Hemnes A, Horn EM, Lammi M, Mathai S, McConnell JW, Presberg K, Robinson J, Sager J, **Shlobin OA**, Simon M, Thenappan T, Ventetuolo C, Al-Naamani N. Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR). *Ann Am Thorac Soc* 2020 Oct 21. [Epub ahead of print] PubMed PMID: 33085915
- **Shlobin OA**, Kouranos V, Barnett S, Alhamad EH, Culver DA, Barney J, Cordova FC, Carmona EM, Scholand MB, Wijnsbeek M, Ganesh S, Birring SB, O'Hare L, Baran JM, Cal JG, Lower EE, Engel PJ, Wells AU, Nathan SD, Baughman RP. Survival of Patients with Sarcoidosis Associated Pulmonary Hypertension: Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension: Results from a Multi-National Registry Cohort. *Eur Respir J* 2020; 55:1901747. [<https://doi.org/10.1183/13993003.01747-2019>].
- DesJardin JT, Kolaitis NA, Kime N, Kronmal RA, Benza RL, Elwing JM, Lammi MR, McConnell JW, Presberg KW, Sager JS, **Shlobin OA**, De Marco T, PHAR Investigators. Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: baseline results from the Pulmonary Hypertension Association Registry. *J Heart Lung Transplant* 2020; 39(9):945-953. doi: 10.1016/j.healun.2020.05.005. Epub 2020 May 16.
- **King CK, Shlobin OA**. The Trouble with Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. *Chest* 2020 May 7:S0012-3692(20)30872-2. doi: 10.1016/j.chest.2020.04.046.
- **Aryal A, King CS**. Critical care of patients with pulmonary arterial hypertension. *Curr Opin Pulm Med* 2020, 26:414–421,
- **Khangoora VS, Shlobin OA**. Evolving spectrum of treatment for CTEPH. *Curr Opin Pulm Med* 2020, 26:406–413.
- **Aryal S, Khangoora V, Nathan SD**. Lung Transplantation for Pulmonary Hypertension. For *Encyclopedia of Respiratory Medicine* 2020. 2nd Edition Medicine published by Elsevier. <https://doi.org/10.1016/B978-0-12-801238-3.11655-1>
- **Aryal S, Ahmad K, Nathan SD**. Group 3 PH: Clinical Features and Treatment: For *Encyclopedia of Respiratory Medicine*, 2020 2nd Edition Medicine published by Elsevier. <https://doi.org/10.1016/B978-0-12-801238-3.11655-1>
- **Nathan SD**, Flaherty K, Glassberg MK, Raghu G, Swigris J, Alvarez R, Ettinger N, Loyd J, Fernandes P, Gillies H, Shah P, Dekker M, Lancaster L. A Randomized, double-blind, placebo-controlled study to assess the

safety and efficacy of pulsed, inhaled nitric oxide (iNO) at a dose of 30 mcg/kg-IBW/hr (iNO 30) in subjects at risk of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF) receiving Oxygen Therapy. *Chest* 2020 158:637-645.

- Clapham KR, Rao Y, Sahay S, Sauler M, Lee PJ, **Psootka MA**, Fares WH, Ahmad T. PECAM-1 is Associated With Outcomes and Response to Treatment in Pulmonary Arterial Hypertension. *Am J Cardiol* 2020; 127:198-199.
- Clapham KR, Rao Y, Sahay S, Sauler M, Lee PJ, **Psootka MA**, Fares WH, Ahmad T. PECAM-1 is Associated With Outcomes and Response to Treatment in Pulmonary Arterial Hypertension. *Am J Cardiol* 2020 Jul 15; 127:198-199. doi: 10.1016/j.amjcard.2020.04.031. Epub 2020 Apr 29. PMID: 32430164.
- Clapham KR, Rao Y, Sahay S, Sauler M, Lee PJ, **Psootka MA**, Fares WH, Ahmad T. PECAM-1 is Associated With Outcomes and Response to Treatment in Pulmonary Arterial Hypertension. *Am J Cardiol* 2020 Jul 15; 127:198-199. doi: 10.1016/j.amjcard.2020.04.031. Epub 2020 Apr 29. PMID: 32430164.
- Myc LA, Solanki JN, Barros AJ, Nuradin N, Nevulis MG, Earasi K, Richardson ED, Tsutsui SC, Enfield KB, Teman NR, Haskal ZJ, Mazimba S, **Kennedy JLW**, Mihalek AD, Sharma AM, Kadl A. Adoption of a dedicated multidisciplinary team is associated with improved survival in acute pulmonary embolism. *Respiratory Research* 2020; 21: 159, PMID 32571318.
- **Khangoora VS, Shlobin OA**. The Evolving spectrum of treatment for CTEPH. *Curr Opinion in Pulm Med* 2020; 26(5):406-413. doi: 10.1097/MCP.0000000000000696. PMID: 32657835.

2021

- Kolaitis N, Zamanian R, De Jesus Perez V, Badesch D, Benza R, Burger C, Chakinala M, Elwing J, Feldman J, Lammi M, Mathai S, McConnell J, Presberg K, Robinson J, Sager J, **Shlobin OA**, Simon M, Kawut S, Glidden D, Singer J, De Marco T. Clinical differences and outcomes between methamphetamine-associated and idiopathic PAH in the Pulmonary Hypertension Association Registry. *Ann Am Thorac Soc* 2021; 18(4):613-622. doi: 10.1513/AnnalsATS.202007-774OC.
- Waxman A, Restrepo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, Allen R, Feldman J, Argula R, Smith P, Rollins K, Deng CQ, Peterson L, Bell H, Tapson V, **Nathan SD**. Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Interstitial Lung Disease. *N Engl J Med* 2021; 384:325-334.
- Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, Campos SV, Christon LM, Cypel M, Dellgred G, Hartwig MG, Siddhartha KG, Kolaitis NA, Kotloff RM, Patterson CM, **Shlobin OA**, Smith PJ, Sole A, Solomon M, Weill D, Wijisenbeek MS, Willemse BWM, Arcasoy SM, Ramos KJ. ISHLT consensus document for the selection of lung transplant candidates: An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. Accepted by JHLT July 2021 (section on Pulmonary HTN written by OAS).
- Chandel A, Verster A, Rahim H, **Khangoora V, Nathan SD, Ahmad K, Aryal S, Bagnola A, Singhal A, Brown AW, Shlobin OA, King CS**. Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension. *Pulmonary Circulation* 2021 epub <https://doi.org/10.1177/20458940211012366>.
- Desai M, Osborn E, **King C, Shlobin OA, Psootka M**, Ryan L, Akhtar SJ, Singh R. Extracorporeal life support for cardiogenic shock during pregnancy and postpartum: a single center experience. *Perfusion* (Sage Journals) 2021;1-6.
- Maron BA, Abman SH, Elliott CG, Frantz RP, Hopper RK, Horn EM, Nicolls MR, **Shlobin OA**, Shah SJ, Kovacs G, Olschewski H, Rosenzweig EB. Pulmonary arterial hypertension: Diagnosis, treatment, and novel advances: State-of-the-Art. *Am J Respir Crit Care Med* 2021; 203(12):1472-1487. doi: 10.1164/rccm.202012-4317SO.
- **Nathan SD**, Barnett SD, **King CS**, Provencher S, Barbera A, Pastre J, **Shlobin OA**, Seeger W. Impact of the new definition for Pulmonary Hypertension in patients with lung disease: An analysis of the UNOS database. *Pulmonary Circulation* 2021; 11(2) 1–7.
- Mazimba S, Ginn G, Mwansa H, Laja O, Jeakeng C, Elumogo C, Patterson B, **Kennedy JLW**, Mehta N, Hossack JA, Parker AM, Mihalek A, Tallaj J, Sodhi N, Kwon Y, Pamboukian SV, Adamson PB, Bilchick KC. Pulmonary artery proportional pulse pressure (PAPP) index identifies patients with improved survival

from the CardioMEMS implantable pulmonary artery pressure monitor. *Heart, Lung, and Circulation* 2021, DOI: 10.1016/j.hlc.2021.03.004 PMID: 33863665.

- Yau P, Lat T, **Shlobin OA**, Malave A, Levine DJ. Pulmonary vascular disease and transplant in advanced lung diseases (Chapter 24). *Pulmonary Vascular Disorders*. Edited by Carbone RG, Puppò F and Tapson VF (Nova Medicine & Health 2021).
- Behr J, **Nathan SD**, Wuyts WA, Mogulkoc Bishop N, Bouros DE, Antoniou K, Guiot J, Kramer MR, Kirchgaessler K, Bengus M, Gilberg F, Perjesi A, Harari S, Wells AU. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension. *Lancet Respir Med* 2021; 9:85–95.
- **Nathan SD**, Cottin V, Behr J, Hoeper MM, Martinez F, Corte T, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Ley-Zaporozhan J, Müller-Lisse GU, Scholle FD, Brueggenwerth G, Busse D, Nikkho S, Wells AU. Impact of lung morphology on clinical outcomes with riociguat in the RISE-IIP study. *J Heart Lung Transplant* 2021;40:494–503
- DuBrock H, **Nathan SD**, Kolaitis N, Mathai S, Reeve B, Martin S, Olayinka-Amao B, Classi P, Nelsen A. The Patient Experience of Symptoms and Impacts in WHO Group 3 Pulmonary Hypertension. *Pulm Circ* 2021; 11(2):20458940211005641. doi: 10.1177/20458940211005641
- **Nathan SD**, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, Zerda DDL, Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards L, Nelsen A, Tapson V. Inhaled Treprostinil and FVC change in Patients with Interstitial Lung Disease and associated Pulmonary Hypertension. *Lancet Res Med* 2021. Published online June 29, 2021. [https://doi.org/10.1016/S2213-2600\(21\)00165-X](https://doi.org/10.1016/S2213-2600(21)00165-X)